Clinical Use and Safety of the Fentanyl Transdermal Therapeutic System (TTS) in the Management of Pain in Patients With Cancer

• Status: Completed
• Trial end date: 1988-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to establish the clinical utility and safety of fentanyl TTS (a transdermal patch delivering the narcotic pain reliever fentanyl) in the treatment of pain in patients with cancer.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alza Corporation, DE, USA
• Treatments: Fentanyl

Criteria

Inclusion Criteria:

• Patients currently taking narcotic analgesics for relief of cancer pain

• Able to communicate effectively

• Living with a constant caretaker

• Who have achieved a stabilized morphine dose that provides adequate pain control

Exclusion Criteria:

• Patients with a life expectancy of less than 30 days

• Having history of carbon dioxide (CO2) retention or other cardiac, respiratory or nervous system disease (precludes participation because of the potential for respiratory depression)

• Has severe renal or hepatic insufficiency, active skin disease, a history of allergic reactions to narcotics, or a history of narcotic abuse prior to treatment with narcotics for cancer-related pain

• Has a mental or psychiatric disease

• If female of child-bearing potential, currently pregnant or not practicing an acceptable method contraception